Savara Inc., a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced the issuance of inducement awards to five new employees under its 2021 Inducement Equity Incentive Plan. On May 21, 2025, the company's Compensation Committee granted options to purchase a total of 85,000 shares of Savara's common stock, along with restricted stock units (RSUs) covering 75,000 shares. The stock options are priced at $2.91 per share, reflecting the closing trading price on the grant date, and feature a 10-year term with vesting occurring quarterly over four years. The RSUs will vest in full after two years, contingent on continued employment. These awards serve as a material inducement for the employees' decision to join Savara.